Pancreatic Cancer Research

GrantR01CA

Intersection of cytoskeletal regulation with tumor cell metabolism

Activity
R01
Institute
CA
Fiscal years
2024–2026
Amount counted
$2,145,395

These are registry fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Abstract public domain (NIH RePORTER)

SUMMARY Pancreatic cancer (PDAC) is particularly lethal, due in part to a resistance to therapies and a high incidence of metastasis. The overall goal of our research program is to define the molecular mechanisms regulating tumor progression and metastasis of PDAC, thereby identifying new therapeutic strategies to improve patient survival. This proposal focuses on an activator of the invasive cytoskeletal machinery, the proto-oncogene Vav1, which is a GTP exchange factor and activator of the potent Rac/Cdc42 small GTPases that regulate actin dynamics. Vav1 is aberrantly expressed in a subset of pancreatic tumors and correlates with a poor prognosis. Here we have identified a novel role for Vav1 in the regulation of glutamine metabolism that we believe contributes to cellular energy levels, thereby integrating a potent pro-invasive factor with an essential metabolic axis in PDAC. Vav1 promotes the conversion of glutamine to glutamate via the enzyme glutaminase (GLS1). Further, we have identified novel mechanisms by which the glutamine/glutamate axis contributes to tumor progression and metastasis through both localized energy production and through paracrine signaling by both glutamate and inflammatory cytokines. Our substantial preliminary data support the hypothesis for this proposal that ectopic expression of the Rac/Cdc42 exchange factor Vav1 regulates glutamine metabolism to link nutrient status to actin dynamics, invasion, and proliferation. Using a combination of cell biology, live cell fluorescence microscopy, biochemistry, and in vivo models, we will test this hypothesis by investigating how Vav1 amplifies glutamine catabolism (Aim 1), and how glutamate production drives tumor progression and metastasis in pancreatic tumor cells (Aim 2). Successful completion of this research will provide fundamental mechanistic advances in our understanding of the metabolic dependencies of PDAC, identify therapeutic vulnerabilities for patients with Vav1- positive tumors, and establish novel links between cytoskeletal signaling and glutamine metabolism.

Public health relevance public domain (NIH RePORTER)

PROJECT NARRATIVE Pancreatic cancer remains one of the most lethal cancers. This proposal will address the mechanisms by which pancreatic tumor cells grow and metastasize via coordinating the cytoskeletal regulatory machinery with a key amino acid metabolism pathway. Using a comprehensive approach that includes biochemical, cell biological, and mouse models, the information resulting from this research will expand our mechanistic understanding of pancreatic cancer, ideally identifying novel therapeutic targets and strategies to improve the survival of pancreatic cancer patients.